Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma.

Oncology reports·2024

Same author

Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models.

Frontiers in immunology·2023

Same author

Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy.

Frontiers in immunology·2023

Same author

Editorial: Immunotherapy for Prostate Cancer - turning the immunological desert into an oasis of hope.

Frontiers in oncology·2022

Same author

Cytotopic (Cyto-) IL-15 as a New Immunotherapy for Prostate Cancer: Recombinant Production in <i>Escherichia coli</i> and Purification.

Frontiers in molecular biosciences·2021

Same author

Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer.

Frontiers in oncology·2021

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Lenalidomide: a novel anticancer drug with multiple modalities.

Christine Galustian¹, Angus Dalgleish

¹Division of Cellular and Molecular Medicine, Department of Oncology, St Georges University of London, Cranmer Terrace, Tooting, London. cgalusti@sgul.ac.uk

Expert Opinion on Pharmacotherapy

|February 25, 2009

Summary

This summary is machine-generated.

Lenalidomide is a key immunomodulatory drug for treating multiple myeloma and myelodysplastic syndromes. Recent breakthroughs highlight its effectiveness and FDA approval, establishing it as a leading cancer therapeutic.

Related Experiment Videos

Last Updated: Jun 25, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Area of Science:

Oncology
Pharmacology
Immunology

Background:

Lenalidomide (Revlimid) is an immunomodulatory drug that has gained prominence in cancer therapy over the last five years.
It is a primary treatment for multiple myeloma and del-5q myelodysplastic syndromes.
Lenalidomide has been investigated for various other cancers, including leukaemias, lymphomas, and solid tumours.

Purpose of the Study:

To review key clinical and mechanistic advancements of lenalidomide.
To highlight lenalidomide's role as a leading cancer therapeutic.

Main Methods:

Review of clinical data and mechanistic studies related to lenalidomide.
Analysis of FDA approvals and therapeutic applications.

Main Results:

Lenalidomide is a lead therapeutic for multiple myeloma and del-5q myelodysplastic syndromes.
Significant development includes FDA approval for previously treated multiple myeloma in combination with dexamethasone.
Lenalidomide has shown potential in trials for various other leukaemias, lymphomas, and solid tumours.

Conclusions:

Lenalidomide has emerged as a significant and leading therapeutic agent in cancer treatment.
Clinical and mechanistic breakthroughs support its established role in oncology.